ImmunityBio Announces Board and Executive Changes
Ticker: IBRX · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
TL;DR
ImmunityBio shakes up its board and exec comp. Big changes ahead?
AI Summary
ImmunityBio, Inc. announced on February 7, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain directors and officers, the election of new directors, and adjustments to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts that may impact future performance.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- February 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37507 (filing_id) — SEC File Number
- 43-1979754 (tax_id) — IRS Employer Identification No.
- 3530 John Hopkins Court (address) — Business and Mail Address
FAQ
Who are the directors or officers that have departed from ImmunityBio, Inc.?
The filing indicates the departure of certain directors or officers, but specific names are not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 7, 2025.
What is the state of incorporation for ImmunityBio, Inc.?
ImmunityBio, Inc. is incorporated in Delaware.
What is the SEC file number for ImmunityBio, Inc.'s 8-K filing?
The SEC file number is 001-37507.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 836 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2025-02-12 21:16:11
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IBRX Nasdaq Global Select
Filing Documents
- d933627d8k.htm (8-K) — 42KB
- 0001193125-25-025324.txt ( ) — 159KB
- ibrx-20250207.xsd (EX-101.SCH) — 3KB
- ibrx-20250207_lab.xml (EX-101.LAB) — 17KB
- ibrx-20250207_pre.xml (EX-101.PRE) — 11KB
- d933627d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover page interactive data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Date: February 12, 2025 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer